Breaks Categories: News

ThursdayJun 09, 2022 2:14 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.…

Continue Reading

WednesdayJun 08, 2022 12:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

Continue Reading

TuesdayJun 07, 2022 10:15 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as…

Continue Reading

MondayJun 06, 2022 2:07 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter…

Continue Reading

FridayJun 03, 2022 2:28 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products…

Continue Reading

ThursdayJun 02, 2022 2:04 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will…

Continue Reading

ThursdayJun 02, 2022 11:39 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in…

Continue Reading

WednesdayJun 01, 2022 1:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022, at 1 p.m. PT. According to the announcement, 2,927,321 shares of the company were represented in person or by proxy during the meeting; that number comprised 49.2% of Lexaria’s issued share capital as of April 4, 2022, which is the record date of the meeting. All matters voted on during the meeting were passed by a majority. Those matters included electing Chris Bunka, John Docherty,…

Continue Reading

TuesdayMay 31, 2022 12:44 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Launch of JustCBD Products on Amazon.co.uk

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its wholly-owned subsidiary JustCBD will be launching its line of Novel Foods-registered CBD products on Amazon.co.uk. Since its entry into the now £700 million CBD market in October 2021, Amazon U.K. has expanded the initial pilot-only program to include vendors who have demonstrated compliance with U.K. CBD Novel Food regulations. Producers awarded U.K. Novel Food authorization must prove the product is safe for consumption and labeled correctly. “With health and wellness playing an increasingly important role in customers’ lives, we are…

Continue Reading

MondayMay 23, 2022 11:05 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Acquisition of Masaya CB Brand

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has signed an agreement to acquire Masaya and its patent-pending CBD formulations, including Masaya Pure. The agreement was made with leading cell biologist Dr. Annabelle Manalo-Morgan, PhD, who created and owns the brand; Manalo-Morgan is a member of Flora Growth’s board of directors and is the company’s scientific advisor. According to the announcement, Masaya’s exclusive CBD oil formulations contain no THC and have garnered numerous testimonials. The brand will be the first offering from Flora Life Sciences in the United States, and the…

Continue Reading